Omicron virus: Some of what we know
|It is different
The Omicron variant has 30 changes to it including a small insertion in the spike protein and three small deletions. Around 50% of these changes are in the receptor-binding domain – this is the part of the spike protein used to bind to human ACE-2, which is the enzyme the coronavirus targets to enter cells and infect a person. If there are mutations here this makes the spike protein less recognizable to the antibodies made in response to either vaccination or natural antibodies. The bottom line is that the Omicron is different.
It is a worry
The concern is that these changes above mean that the virus transmits more quickly. Early PCR tests showed that 90% of 1,100 new cases reported November 24 in a SA province were caused by the new variant. SA President Cyril Ramaphosa said that the average daily cases rose from 500 cases in the previous week to 1,600.
It is also uncertain how bad it is
Being more transmissible is not necessarily a bad thing if the virus has milder effects. It could actually be a good thing as Eamonn pointed out that catching a less severe variant results in lesser illness and then confers ‘immunity’. Anecdotal comments suggest that the variant is not an obvious concern.
Novavax, Moderna, & Johnson & Johnson are all onto testing the new variant against its vaccines. Even the variant is able to evade the current vaccine Moderna’s Chief Medical Officer said a new vaccine variant could be ready early next year.
The one thing that strikes is that this variant news broke over the US Thanksgiving holiday, a natural downtime for economic data and news activity. There are so many unknowns here there is a strong case for both caution and dip-buying. At any rate, note that vaccine companies like Moderna are confident in being able to put in a fresh response even if the variant does evade existing vaccines. This would make dip-buying in NZDJPY attractive around current levels. However, note that the Moderna CEO now thinks that the current vaccine will be much less effective against the variant, so that is a near-term downside in risk.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.